Humana Inc NYSE:HUM Price, Chart, News & Insight

Humana Stock Climbs 2% Premarket After Wells Fargo Upgrades Shares to Overweight

Humana (NYSE: HUM) shares rose nearly 2% in premarket trading on Monday after Wells Fargo upgraded the health insurer to *Overweight* from *Reduce*, reflecting growing confidence in the company's earnings outlook and recovery prospects.

Why Is Humana Stock Rising Today?

The primary catalyst behind Monday's premarket gain was Wells Fargo's significant rating upgrade, moving Humana directly from Reduce to Overweight.

The upgrade suggests the investment bank believes the company's risk-reward profile has improved following a challenging period for the managed care industry, with recent headwinds increasingly reflected in the stock's valuation.

Medicare Advantage Recovery Boosts Sentiment

Humana has spent the past year navigating higher medical costs and reimbursement pressure within the Medicare Advantage market, factors that weighed heavily on earnings expectations across the health insurance sector.

However, investor sentiment has improved as insurers have adjusted pricing, refined plan offerings, and implemented cost-control measures aimed at restoring profitability. The market is also becoming more optimistic that earnings pressure from elevated medical utilization could moderate over the coming quarters.

Despite Monday's premarket gain, Humana shares remain below their historical highs, although the stock has staged a strong recovery over recent months.

What Investors Are Watching Next

Investors will closely watch Humana's upcoming quarterly earnings for updates on Medicare Advantage enrollment, medical cost trends, and the company's 2027 outlook. Commentary on reimbursement rates, benefit design, and margin recovery will also be key drivers of investor sentiment.

The Wells Fargo upgrade appears to have improved confidence in Humana's recovery story, helping lift the stock in premarket trading as investors increasingly expect the company to benefit from improving fundamentals across the Medicare Advantage business.

💬 🔗

European Investor 07-13-26

Humana reported strong first-quarter 2026 results and reaffirmed its full-year adjusted outlook, supported by solid performance in its insurance and healthcare services segments.

GAAP EPS came in at $9.83, while adjusted EPS reached $10.31, landing at the high end of the company’s expectations relative to its full-year guidance. The insurance segment benefit ratio was 89.4%, slightly better than guidance, reflecting disciplined cost management.

Humana reaffirmed its full-year 2026 adjusted EPS guidance of at least $9.00, while lowering GAAP EPS guidance to at least $8.36 from $8.89, indicating some non-operational pressures. The company also maintained expectations for approximately 25% growth in Medicare Advantage membership.

Operationally, Humana continued expanding its healthcare services footprint. CenterWell saw strong patient growth, including contributions from the MaxHealth acquisition, while new state-based contracts and partnerships in pharmacy services supported further expansion.

The results highlight continued execution of Humana’s integrated care strategy and growth in both insurance and care delivery businesses.

Source: Company press release

💬 🔗

Global Finance News 04-30-26

Humana Inc. (NYSE: HUM) declared a cash dividend to stockholders of $0.885 per share payable on July 31, 2026 to stockholders of record as of the close of business on June 26, 2026.

💬 🔗

WS Investor 04-16-26

Humana announced the completion of a $1.0 billion public offering of fixed-to-fixed rate junior subordinated notes due 2056. The notes were issued at 6.625% of the principal amount.

The company expects to receive approximately $986 million in net proceeds after underwriting discounts and expenses. Humana said the funds will be used for general corporate purposes, including the possible repayment of existing debt such as borrowings under its commercial paper program.

The offering was managed by several financial institutions acting as joint book-running managers, including Goldman Sachs, JPMorgan, Mizuho Securities, Truist Securities and Wells Fargo Securities.
Business Wire

💬 🔗

European Investor 03-10-26

Humana Inc. (NYSE: HUM) announced that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026.

💬 🔗

WS Investor 02-19-26

Humana Inc. reported a fourth-quarter 2025 net loss but delivered full-year results in line with management expectations, while introducing cautious 2026 earnings guidance reflecting Medicare Star Ratings headwinds.

In the fourth quarter of 2025, Humana posted a GAAP net loss per share of $6.61, compared with a loss of $5.76 in the prior-year period. Adjusted net loss per share was $3.96, versus $2.16 a year earlier. Consolidated pretax loss totaled $1.01 billion on a GAAP basis, while adjusted pretax loss was $596 million.

For full-year 2025, GAAP EPS was $9.84, compared with $9.98 in 2024. Adjusted EPS increased to $17.14 from $16.21 in the prior year. Full-year consolidated revenues reached $129.7 billion, up from $117.8 billion in 2024.

The Insurance segment reported a fourth-quarter GAAP benefit ratio of 93.1%, while the full-year benefit ratio was 90.4%, slightly better than the company’s guidance range of 90.1% to 90.5%. Adjusted consolidated operating cost ratio improved to 11.5% for the year.

Operationally, the company highlighted continued platform expansion. CenterWell Senior Primary Care grew by 100,600 patients in 2025, an increase of more than 25%, including approximately 32,000 patients from the acquisition of The Villages Health. Humana’s Medicaid footprint now spans 13 states, with Georgia and Texas expected to launch in 2027.

For 2026, Humana introduced GAAP EPS guidance of at least $8.89 and adjusted EPS guidance of at least $9.00. The anticipated year-over-year decline primarily reflects the impact of lower Medicare Star Ratings for Bonus Year 2026, net of mitigation efforts. The company expects individual Medicare Advantage membership growth of approximately 25% in 2026, driven by new sales and improved retention.

Management reiterated confidence in its consumer-focused strategy, while acknowledging regulatory and Star Ratings-related pressures heading into 2026.

Source: Business Wire.

💬 🔗

WS Investor 02-11-26

Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2025 at 6:00 a.m. Eastern time on February 11, 2026.

💬 🔗

Global Finance News 02-11-26

Humana will release its fourth-quarter 2025 financial results on February 11, 2026, at 6:00 a.m. ET. The company will host a live Q&A session at 8:00 a.m. ET to discuss the results and provide earnings guidance for 2026.

💬 🔗

The Investor 01-10-26

Humana announced a planned leadership transition within its insurance segment, with Insurance Segment President George Renaudin set to retire by the third quarter of 2026 after a 29-year career at the company. Renaudin has played a central role in building and expanding Humana’s Medicare Advantage and Medicaid businesses and will remain in place during the transition to ensure continuity, later serving as a strategic advisor through at least the end of 2026.

As part of the transition, Humana will appoint Aaron Martin as President of Medicare Advantage in January 2026. Martin will also be a member of the Enterprise Leadership Team and will initially report jointly to Renaudin and CEO Jim Rechtin. Following Renaudin’s retirement, Martin is expected to succeed him as Insurance Segment President. At that time, John Barger will be promoted to President of Medicare Advantage, reporting to Martin. Barger currently leads Humana’s Medicaid and Dual Eligible programs and brings more than 25 years of experience at the company.

Humana said the leadership changes are designed to strengthen operational focus across its insurance businesses, consolidate Medicare Advantage leadership, and support the company’s long-term strategy centered on value-based care and consumer-focused healthcare delivery.

Source: Business Wire

💬 🔗

Global Finance News 12-16-25

Humana Inc. (NYSE: HUM) reported in a new Form 8-K that senior management will meet with investors and analysts throughout December and will reaffirm the company’s full-year 2025 earnings outlook. The company continues to expect about 12.26 dollars in diluted EPS and roughly 17.00 dollars in adjusted EPS for FY2025, consistent with guidance issued on 5 November. Humana provided a reconciliation showing that adjusted EPS excludes items such as intangible amortization, put/call valuation adjustments, value-creation initiatives and impacts related to business exits, litigation settlements and impairments. The company noted that while GAAP EPS may change due to strategic initiatives, it does not anticipate changes to its adjusted EPS outlook.

💬 🔗

Global Finance News 12-01-25

NYSE:HUMFollow

NYSE:HUM